PMID- 27916484
OWN - NLM
STAT- MEDLINE
DCOM- 20180306
LR  - 20221207
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Mar
TI  - Associations between FGF21, osteonectin and bone turnover markers in type 2 
      diabetic patients with albuminuria.
PG  - 583-588
LID - S1056-8727(16)30856-X [pii]
LID - 10.1016/j.jdiacomp.2016.11.012 [doi]
AB  - AIM: We measured the levels of bone turnover markers (BTMs) in patients with 
      early diabetic nephropathy from type 2 diabetes mellitus (T2DM), and investigated 
      the associations of BTMs with adipokines, serum fibroblast growth factor-21 
      (FGF21) and osteonectin. METHODS: We included 159 males and 300 females with T2DM 
      in this cross-sectional study. Clinical characteristics, BTMs and adipokines 
      levels were measured. RESULTS: One-hundred and ninety-two (41.8%) patients 
      presented with albuminuria. Patients with albuminuria had significantly higher 
      levels of serum osteonectin (P<0.0001) and FGF21 (P=0.0125) than those with 
      normoalbuminuria. Serum levels of P1NP were slightly lower among patients with 
      albuminuria (P=0.031), but the difference disappeared after adjusting for FBG, 
      PBG, and HbA1c. Serum FGF21 levels were independently and negatively related to 
      eGFR (overall beta=-0.161, P=0.001; albuminuria group beta=-0.240, P=0.001) but not 
      related to uACR. While Osteonectin was independently and positively related to 
      uACR (overall beta=0.209, P=0.001; albuminuria group beta=0.170, P=0.021). The levels 
      of serum FGF21 were independently inversely related with P1NP (overall beta=-0.192, 
      P<0.0001; albuminuria group beta=-0.195, P=0.031). CONCLUSIONS: Our results suggest 
      that persistent hyperglycemia may inhibit bone formation. Both osteonectin and 
      FGF21 were associated with early nephropathy in T2DM patients, albeit with 
      different patterns.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Xu, Lingling
AU  - Xu L
AD  - Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, 
      Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 
      Shuaifuyuan No.1, Dongcheng District, Beijing 100730, China.
FAU - Niu, Meng
AU  - Niu M
AD  - Department of Endocrinology, Traditional Chinese Medicine Hospital of Muping 
      District of Yantai City, Yantai, Shandong, China.
FAU - Yu, Weihong
AU  - Yu W
AD  - Department of Ophthalmology, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Science, Beijing, China.
FAU - Xia, Weibo
AU  - Xia W
AD  - Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, 
      Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 
      Shuaifuyuan No.1, Dongcheng District, Beijing 100730, China.
FAU - Gong, Fengying
AU  - Gong F
AD  - Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, 
      Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 
      Shuaifuyuan No.1, Dongcheng District, Beijing 100730, China.
FAU - Wang, Ou
AU  - Wang O
AD  - Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, 
      Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 
      Shuaifuyuan No.1, Dongcheng District, Beijing 100730, China. Electronic address: 
      wang_ou2010@126.com.
LA  - eng
PT  - Journal Article
DEP - 20161117
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Biomarkers)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Osteonectin)
RN  - 0 (fibroblast growth factor 21)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 62031-54-3 (Fibroblast Growth Factors)
SB  - IM
MH  - Aged
MH  - Albuminuria/*etiology
MH  - Biomarkers/blood/urine
MH  - Bone Resorption/complications
MH  - China
MH  - Combined Modality Therapy
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood/*complications/therapy/urine
MH  - Diabetic Nephropathies/*complications/physiopathology
MH  - Female
MH  - Fibroblast Growth Factors/*blood
MH  - Glomerular Filtration Rate
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/prevention & control
MH  - Kidney/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Osteonectin/*blood
MH  - Osteoporosis/*complications
MH  - Renal Insufficiency/*complications/physiopathology
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Bone turnover marker
OT  - Diabetic nephropathy
OT  - Fibroblast growth factor-21
OT  - Osteonectin
OT  - Type 2 diabetes
EDAT- 2016/12/06 06:00
MHDA- 2018/03/07 06:00
CRDT- 2016/12/06 06:00
PHST- 2016/06/24 00:00 [received]
PHST- 2016/11/09 00:00 [revised]
PHST- 2016/11/13 00:00 [accepted]
PHST- 2016/12/06 06:00 [pubmed]
PHST- 2018/03/07 06:00 [medline]
PHST- 2016/12/06 06:00 [entrez]
AID - S1056-8727(16)30856-X [pii]
AID - 10.1016/j.jdiacomp.2016.11.012 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2017 Mar;31(3):583-588. doi: 
      10.1016/j.jdiacomp.2016.11.012. Epub 2016 Nov 17.